MetaCap

MaxCyte (MXCT) vs NRC Health (NRC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NRC Health (NRC) has outperformed MaxCyte (MXCT) over the past year, gaining 42.5% versus a loss of 18.0%. Over five years, NRC leads with a -39.0% price change compared with -85.9% for MXCT. NRC Health is the larger company by market cap ($533.9 million vs $141.5 million), about 3.8 times the size.

NRC Health pays a dividend yielding 2.54%, while MaxCyte does not currently pay one. NRC Health converts more of its revenue into profit, with a net margin of 8.4% versus -135.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MXCT-17.96%NRC+42.47%
+59%-3%-65%
Nov 21, 20251 yearNov 20, 2026
MXCT-89.29%NRC-40.86%
+15%-43%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MXCT versus NRC key metrics
MetricMXCTNRC
Share price$1.37$25.16
Market cap$141.45M$533.93M
1-day change+7.03%+0.68%
YTD return-11.61%+34.04%
1-year return-17.96%+42.47%
5-year return-85.92%-38.98%
P/E ratio (TTM)—93.19
Forward P/E—23.74
EPS (TTM)$-0.26$0.27
Dividend yield0.00%2.54%
Annual dividend$0.00$0.64
Revenue (latest FY)$33.03M$137.39M
Revenue growth (YoY)-14.50%-3.96%
Net income (latest FY)$-44.63M$11.60M
Gross margin81.16%—
Operating margin-157.14%16.44%
Net margin-135.14%8.44%
52-week high$1.80$27.60
52-week low$0.643$11.74
Distance from 52-week high-23.89%-8.84%
Analyst consensusstrong_buynone
Avg. price target upside+200.00%+7.31%
Average volume1.04M110.81K
Shares outstanding103.25M21.22M
Employees91357
SectorHealth CareHealth Care
IndustryBiotechnology: Commercial Physical & Biological ResarchBiotechnology: Commercial Physical & Biological Resarch

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NRC Health is about 3.8 times larger than MaxCyte by market value ($533.93M vs $141.45M).
  • NRC has outperformed MXCT by 60.4 percentage points over the past year.
  • NRC Health offers a meaningfully higher dividend yield (2.54% vs 0.00%).
  • NRC Health is more profitable, keeping 8.4 cents of every revenue dollar as net income versus -135.1 cents for MaxCyte.
  • NRC Health grew revenue faster in its latest fiscal year (-3.96% vs -14.50%).

About MaxCyte

MXCT stock →

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.

Health Care · Biotechnology: Commercial Physical & Biological Resarch · 91 employees

About NRC Health

NRC stock →

NRC Health provides analytics and insights to measure and improve patient and employee experience for healthcare organizations in the United States. The company offers market experience solutions, a subscription-based services for improved tracking of awareness, perception, and consistency of healthcare brands; assessment of differentiators; and segmentation tools to evaluate the needs, wants, and behaviors of communities through assessments.

Health Care · Biotechnology: Commercial Physical & Biological Resarch · 357 employees

MXCT vs NRC FAQ

Which is bigger, MaxCyte or NRC Health?

NRC Health (NRC) is larger, with a market capitalization of $533.93M compared with $141.45M for MaxCyte (MXCT).

Which stock has performed better over the past year, MXCT or NRC?

NRC returned +42.47% over the past 12 months, compared with -17.96% for MXCT (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, MaxCyte or NRC Health?

NRC Health pays a dividend yielding 2.54%, while MaxCyte does not currently pay a regular dividend.

Are MaxCyte and NRC Health in the same industry?

Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.

More comparisons